# Presidio Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/presidio-medical

- Industry: Medical Devices & Equipment
- Headquarters: San Francisco, US
- Website: www.presidiomedical.com
- Total disclosed funding: $72M
- Latest round: Series C (Jun 26, 2023)
- Investors on record: 4

## About

Presidio Medical, Inc., based in the US, develops groundbreaking neuromodulation therapies to address chronic nociceptive pain, utilizing its proprietary Ultra Low Frequency (ULF™) Neuromodulation System to enhance treatment options for patients.Founded in 2017 and headquartered in San Francisco, US, Presidio Medical, Inc. focuses on creating innovative solutions for chronic pain management. The company has completed 3 funding deals, with the most recent being a Series C round on June 26, 2023, in which it raised USD 72.00 mn led by Deerfield Management Company. Kenneth Wu is the founder, and the current CEO is Michael Onuscheck.Presidio Medical specializes in innovative neuromodulation therapies through its proprietary Ultra Low Frequency (ULF™) Neuromodulation System. This technology addresses chronic nociceptive pain, which traditional treatments often overlook. The ULF™ system uses advanced circuit design and material science to reduce pain responses, serving patients with limited therapeutic options. Presidio’s products are intended for healthcare providers and target markets in North America and Europe, addressing the increasing demand for effective pain management solutions.Presidio Medical generates revenue by selling its ULF™ Neuromodulation System to hospitals and medical facilities, facilitating access to this therapy for patients. Its revenue model is primarily B2B, involving direct sales to medical institutions for clinical use, which may include both one-time purchases of equipment as well as ongoing support partnerships. This strategy aligns the pricing and financial terms with the operational needs of healthcare facilities, emphasizing the therapeutic value of the ULF™ system.In June 2023, Presidio Medical raised USD 72.00 mn in Series C funding, led by Deerfield Management Company, with participation from ShangBay Capital, Action Potential Venture Capital, and Invus. The company plans to utilize this funding to support the clinical trial of the ULF™ SCS system, enhance its production capabilities, and increase its workforce. Presidio aims to broaden its market reach, particularly in North America and Europe, to establish a stronger presence in the evolving pain management landscape.

## Funding rounds

- Series C, Jun 26, 2023, $72M — Invus [DUP], Deerfield Management, Action Potential Venture Capital, ShangBay Capital

## Investors

- Invus [DUP] — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- Action Potential Venture Capital (https://capitalatlas.ai/funds/action-potential-venture-capital) — Series C
- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series C